Rationale


The epidemiology of surgical induced AKI is currently unknown. However, recent reports on incidences of AKI indicate that every second surgical patient is affected by this complication. Since AKI is independently associated with adverse outcomes, an exact knowledge of the occurrence is imperatively needed to enhance the awareness for this critical condition, consequently optimize patient management in order to improve patient outcome. Moreover, it has a high impact on health policy and the results are urgently needed for designing new pre-emptive and therapeutic trials, which is the main goal of the RAPNetwork (Renoprotective Network) supported by the European Society of Anesthesiology (Initiator: Univ.-Prof. Dr. med. Alexander Zarbock).

Study design

EPIS-AKI is an international multi-center, prospective observational study with the aim to include 10,000 patients to clarify the incidence and circumstances of the occurrence of acute kidney injury in patients undergoing major surgery.

The study is also registered at ClinicalTrials.gov.

  • Age ≥ 18 years
  • Major operations with a duration of at least two hours
  • Planned or unplanned admission to the ICU, IMCU or similiar after surgery
  • Written informed consent

  • Pre-existing AKI
  • AKI within the last three months
  • End-stage renal disease with dialysis dependency
  • Kidney transplant

 

Primary Endpoints

  • The occurrence of AKI within 72h after surgery according to the KDIGO criteria

Secondary Endpoints

  • Effect of preoperative risk factors on the incidence of postoperative AKI
  • Effect of predetermined intraoperative factors on the impact of postoperative AKI
  • Biomarkers of AKI (urine for this endpoint will be collected in some centres)
  • Outcomes:
    • Use of renal replacement therapy
    • Length of ICU stay
    • Length of hospital stay
  • Survival
    • ICU mortality
    • Hospital mortality
  • MAKE90 (major adverse kidney events at day 90): combined endpoint consisting of:
    • Mortality
    • Renal replacement therapy
    • Persistent renal dysfunction defined as serum-creatinine ≥ 1.5 times as compared to baseline serum-creatinine

  • Alexander Zarbock
    Department of Anesthesiology, Intensive Care and Pain Medicine
    University Hospital Münster, Münster
    Germany
     
  • Thomas Rimmelé
    Department of Anaesthesiology and Intensive Care Medicine
    Edouard Herriot Hospital, Lyon
    France
     
  • Max Bell
    Department of Perioperative Medicine and Intensive Care
    Karolinska University Hospital, Stockholm
    Sweden
     
  • Nandor Marczin
    Section of Anaesthesia, Pain Medicine and Intensive Care
    Imperial College, London
    United Kingdom
     
  • Stefano Romagnoli
    Department of Anesthesia and Intensive Care
    University of Florence, Azienda Ospedaliero-Universitaria Careggi, Florence
    Italy
     
  • Idit Matot
    Division of Anesthesiology and Intensive Care and Pain Medicine
    Tel Aviv Sourasky Medical Center, Sackler School of Medicine, Tel Aviv
    Israel
 
 
 
 

Current number of registered patients

APPROX. 8.700
in 26 participating countries
(as of November 1st 2021)

CONTACT

Bureau of Clinical Investigations

Department for Anesthesiology,
Intensive Care and Pain Medicine
University Hospital Münster

Albert-Schweitzer-Campus 1
Complex A1

48149 Münster - Germany

T: + 49 251 83-47282
F: + 49 251 83-40501

epis-aki(at)­ukmuenster(dot)­de
epis-aki.ukmuenster.de